Phase 1 Obesity Trial, Recruiting NCT04934228 Sponsor: University of Kansas Medical Center Condition: Obesity
Back to Obesity

Phase 1 Obesity Trial, Recruiting

NCT04934228
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 79 years old, of any gender
  • People with a BMI (body mass index) over 30, which is generally considered obese
  • People with high blood pressure, specifically a reading above 130/80
  • People with elevated insulin resistance, measured by a specific blood test called HOMA-IR with a score above 2.5 (confirm with trial site)
  • People with a waist measurement greater than 102 cm for men, or greater than 88 cm for women
  • People with a fasting blood sugar level below 126 mg/dL (measured after not eating)
  • People with fasting triglyceride levels (a type of fat in the blood) below 250 mg/dL
  • People with an HbA1c level (a measure of average blood sugar over time) below 6.5%
  • People who are willing and able to visit the research lab at Fairway CTSU
  • People who are willing to have a blood sample taken
  • People who are able to sign a written consent form agreeing to participate

Who may not be able to join:

  • People who currently take clonidine or beta-blockers (certain types of blood pressure or heart medications)
  • People who currently smoke, or who have smoked within the past 3 months
  • People with high triglyceride levels (a type of fat in the blood) above 250 mg/dL
  • People who are currently taking any medication for high blood pressure
  • People who have a history of heart disease, including heart attack, stroke, heart failure, stents, bypass surgery, valve problems, or cardiomyopathy (a disease of the heart muscle)
  • People who have a history of neurological disorders (conditions affecting the brain or nervous system)
  • People who have had an organ or tissue transplant
  • People who are currently taking part in another research study, unless it is a registry study only

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Seth W. W Holwerda, PhD, University of Kansas Medical Center

Phone: 9729223230

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
University of Kansas Medical Center
Registry
ClinicalTrials.gov
Start date
1 July 2021
Est. completion
1 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Blood Work: Efficacy of 4-week supply of Clonidine Compared VS 4-week supply of control condition using hydrochlorothiazide (HCTZ) and a separate placebo treatment; Endothelial Cell Sample: Efficacy of 4-week supply of Clonidine Compared VS 4-week supply of control condition using hydrochlorothiazide (HCTZ) and a separate placebo treatment; Adipose Tissue Sample: Efficacy of 4-week supply of Clonidine Compared VS 4-week supply of control condition using hydrochlorothiazide (HCTZ) and a separate placebo treatment; Blood Work: Efficacy of 4-week supply of Clonidine Compared VS 4-week supply of c...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov